Vanta Holdings Inc. Launches Private Placement to Enter U.S. Peptide Market

Vanta Holdings Inc., a consumer health sciences firm, has announced a proposed non-brokered private placement financing. This initiative involves issuing up to 2,500,000 units priced at $1.00 each, aiming to raise $2.5 million. Each unit comprises one common share and one transferable share purchase warrant, with warrants exercisable at $1.25 until mid-2028.

The net proceeds will help bolster Vanta's integrated health sciences platform, facilitate U.S. market entry for peptide products, and support ongoing business development. Completion of the placement is expected by June 30, 2026, in compliance with Canadian Securities Exchange policies.

Insiders may partake in the placement, adhering to specific regulatory exemptions, ensuring minimal impact on market capitalization. The offering is not registered under U.S. securities laws, restricting sales within the U.S.